Literature DB >> 24985962

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Gerhardt Attard1, Matthew R Sydes2, Malcolm D Mason3, Noel W Clarke4, Daniel Aebersold5, Johann S de Bono1, David P Dearnaley1, Chris C Parker1, Alastair W S Ritchie6, J Martin Russell7, George Thalmann8, Estelle Cassoly9, Robin Millman10, David Matheson11, Francesca Schiavone6, Melissa R Spears6, Mahesh K B Parmar6, Nicholas D James12.   

Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24985962     DOI： 10.1016/j.eururo.2014.05.038

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  19 in total

Review 1.  [Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis].

Authors:  A Spek; A Herlemann; C Gratzke; C G Stief
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 2.  [Cytoreductive, radical prostatectomy in metastatic prostate cancer].

Authors:  M Chaloupka; A Herlemann; A Spek; C Gratzke; C Stief
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 3.  Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.

Authors:  Adam B Weiner; Oluwarotimi S Nettey; Alicia K Morgans
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

Review 4.  Synergistic action of image-guided radiotherapy and androgen deprivation therapy.

Authors:  Jennifer A Locke; Alan Dal Pra; Stéphane Supiot; Padraig Warde; Robert G Bristow
Journal:  Nat Rev Urol       Date:  2015-03-24       Impact factor: 14.432

Review 5.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Ashley E Ross; Kenneth J Pienta; Phuoc T Tran; Edward M Schaeffer
Journal:  Nat Rev Urol       Date:  2016-10-11       Impact factor: 14.432

6.  Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

Authors:  Scott Wilkinson; Huihui Ye; Fatima Karzai; Stephanie A Harmon; Nicholas T Terrigino; David J VanderWeele; John R Bright; Rayann Atway; Shana Y Trostel; Nicole V Carrabba; Nichelle C Whitlock; Stephanie M Walker; Rosina T Lis; Houssein Abdul Sater; Brian J Capaldo; Ravi A Madan; James L Gulley; Guinevere Chun; Maria J Merino; Peter A Pinto; Daniela C Salles; Harsimar B Kaur; Tamara L Lotan; David J Venzon; Peter L Choyke; Baris Turkbey; William L Dahut; Adam G Sowalsky
Journal:  Eur Urol       Date:  2021-03-27       Impact factor: 20.096

Review 7.  Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice.

Authors:  Dena R Cohen; Susan Todd; Walter M Gregory; Julia M Brown
Journal:  Trials       Date:  2015-04-22       Impact factor: 2.279

Review 8.  The biology and treatment of oligometastatic cancer.

Authors:  Diane K Reyes; Kenneth J Pienta
Journal:  Oncotarget       Date:  2015-04-20

9.  Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.

Authors:  H B Mistry; M-A Fabre; J Young; G Clack; P A Dickinson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-05-15

10.  Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

Authors:  Nicholas D James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Malcolm D Mason; Christopher C Parker; Alastair W S Ritchie; J Martin Russell; Francesca Schiavone; Gerhardt Attard; Johann S de Bono; Alison Birtle; Daniel S Engeler; Tony Elliott; David Matheson; Joe O'Sullivan; Delia Pudney; Narayanan Srihari; Jan Wallace; Jim Barber; Isabel Syndikus; Mahesh K B Parmar; Matthew R Sydes
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.